Moderna to continue to build large seasonal vaccine franchise over near-term

The company said, “Over the near term, Moderna (MRNA) will continue to build a large seasonal vaccine franchise targeting at-risk populations and propelling the Company to 2028 cash breakeven. The Company expects to invest the cash generated from its marketed products, Spikevax, mRESVIA and mNEXSPIKE-as well as from anticipated launches of influenza, flu/COVID combination and Norovirus vaccines-into its oncology and rare disease programs. Investments in late-stage oncology and rare disease programs set the stage for additional growth in 2027 and 2028, with early-stage pipeline investments expected to mature in 2029 and beyond. Commercial growth drivers include geographic expansion and new product launches. In 2026, the Company expects growth from the annualized impact of long-term partnerships in the UK, Canada and Australia that enhance research and development investment, support national security and defense, and provide revenue visibility through onshore manufacturing. The Company also expects continued strong uptake of mNEXSPIKE in the U.S. and its launch in other countries. In 2027, Europe represents a significant market for respiratory virus vaccines, as a competitor COVID contract lapses and more product approvals are expected. New potential long-term partnerships in Latin America and Asia-Pacific, as well as entry into the flu vaccine market, also position the Company for further expansion. In 2028, Moderna anticipates a first-to-market flu/COVID combination vaccine and continued momentum with a potential novel Norovirus vaccine, expanding its seasonal franchise to as many as six approved products. The Company’s existing commercial infrastructure supports these seasonal vaccine growth drivers. A focused Moderna U.S. commercial team engages the same customers across the retail pharmacy, government and healthcare provider channels, and teams supporting the UK, Canada and Australia partnerships are established. Additionally, Moderna’s EU commercial infrastructure is in place and targeted investments will be made as needed.”